bioRxivMicrobiology
Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles
A. M. Syed, T. Y. Taha, M. M. Khalid, T. Tabata, I. P. Chen, B. Sreekumar, P.-Y. Chen, J. M. Hayashi, K. M. Soczek, M. Ott, J. A. Doudna
Abstract
Newly evolved SARS-CoV-2 variants are driving ongoing outbreaks of COVID-19 around the world. Efforts to determine why these viral variants have improved fitness are limited to mutations in the viral spike (S) protein and viral entry steps using non-SARS-CoV-2 viral particles engineered to display S. Here we show that SARS-CoV-2 virus-like particles can package and deliver exogenous transcripts, enabling analysis of mutations within all structural proteins and rapid dissection of multiple steps in the viral life cycle. Identification of an RNA packaging sequence was critical for engineered transcripts to assemble together with SARS-CoV-2 structural proteins S, nucleocapsid (N), membrane (M) and envelope (E) into non-replicative SARS-CoV-2 virus-like particles (SC2-VLPs) that deliver these transcripts to ACE2- and TMPRSS2-expressing cells. Using SC2-VLPs, we tested the effect of 30 individual mutations within the S and N proteins on particle assembly and entry. While S mutations unexpectedly did not affect these steps, SC2-VLPs bearing any one of four N mutations found universally in more-transmissible viral variants (P199L, S202R, R203M and R203K) showed increased particle production and up to 10-fold more reporter transcript expression in receiver cells. Our study provides a platform for rapid testing of viral variants outside a biosafety level 3 setting and identifies viral N mutations and viral particle assembly as mechanisms to explain the increased spread of current viral variants, including Delta (N:R203M). One-Sentence SummaryR203M substitution within SARS-CoV-2 N, found in delta variant, improves RNA packaging into virus-like particles by 10-fold.
- organism: virus
- assay: spatial transcriptomics
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Enhanced RNA replication and pathogenesis in recent SARS-CoV-2 variants harboring the L260F mutation in NSP6
Taha Y. Taha, Shahrzad Ezzatpour, … Mélanie Ott·PLoS PathogensPeer-reviewed·Mar 31, 2025
- RG203KR mutations in SARS-CoV-2 Nucleocapsid: Assessing the impact using Virus-like particle model system
- Structure-function investigation of a new VUI-202012/01 SARS-CoV-2 variant
Jasdeep Singh, Nasreen Z. Ehtesham, … Seyed E. Hasnain·bioRxiv·Jan 1, 2021
- Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis.
B. A. Johnson, Y. Zhou, … V. D. Menachery·PLOS PathogensPeer-reviewed·Jun 21, 2022
- Nucleocapsid mutation R203K/G204R increases the infectivity, fitness and virulence of SARS-CoV-2
- Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasion